Acid Suppression Should Not Be the First Treatment for Infants With RefluxAcid Suppression Should Not Be the First Treatment for Infants With Reflux https://pediatricsnationwide.org/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150 Mary Bates, PhD Mary Bates, PhD https://secure.gravatar.com/avatar/c6233ca2b7754ab7c4c820e14eb518c8?s=96&d=mm&r=g
- December 27, 2018
- Mary Bates, PhD
Gastroesophageal reflux (GER) is common in infants. Many show no symptoms more serious than agitation and frequent regurgitation, and most cases resolve on their own by the time the child is 1 year old.
Despite a paucity of well-controlled clinical trials, acid suppression medications are commonly prescribed for infants with GER. In a paper published in Pediatric Drugs, physician researchers from Nationwide Children’s Hospital review the data regarding acid suppressants for infants as well as clinical practice guidelines for how and when to use these medications.
“Infant reflux has been an issue for parents since the beginning of time,” says Steven Ciciora, MD, director of division educational activities in the Division of Gastroenterology, Hepatology, and Nutrition at Nationwide Children’s and one of the study’s authors. “What is new is using acid suppression medications designed to help adults with their reflux symptoms.”
While the data supporting the use of acid suppressants such as proton pump inhibitors and histamine-2 receptor antagonists in adults is robust, there is no solid evidence that these medications change outcomes in infant GER. In fact, there are multiple studies that show these drugs may be associated with harmful effects.
“Since these medications change the acid balance in the stomach, and stomach acid helps protect us from pathogens we ingest, they can make that line of defense less effective,” says Dr. Ciciora, who is also an assistant professor of Pediatrics at The Ohio State University College of Medicine. “There are concerns about leaving patients at risk for infections.”
In 2018, the North American and European Societies for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN/ESPGHAN) released updated clinical practice guidelines that emphasize trying non-pharmacologic changes and reducing the use of acid suppressants.
Before considering medication, the guidelines recommend clinicians reassure caretakers that GER is normal and self-limiting and try changes like thickening of feeds, altering the formula or maternal diet protein sources, and providing smaller and more frequent feeds. Subsequent trials of acid suppressants should be kept brief (4-8 weeks).
“No medicine is without risk, including acid suppressants,” says Dr. Ciciora. “For a problem that will likely get better with the passage of time, do you want to submit the child to those risks? Especially when the evidence that the benefit of these medications is about the same as a placebo with no active ingredient whatsoever?”
Dr. Ciciora acknowledges that infant reflux is a common problem that is often distressing for caregivers. But he says that the practitioner’s first step in management should not be acid suppressants.
“In many cases, reassurance and management with non-pharmacologic means can be just as helpful and perhaps safer for the patient,” says Dr. Ciciora. “Not every problem requires a pill for an answer.”
Ciciora, SL and Woodley, FW. Optimizing the use of medications and other therapies in infant gastroesophageal reflux. Pediatric Drugs. 2018 Sep 10. [Epub ahead of print].
This was reviewed by Dr. Ciciora for relevance and accuracy in March 2022.
About the author
You might also like
American Academy of Pediatrics Updates Guidelines for the Management of Neonatal HyperbilirubinemiaAmerican Academy of Pediatrics Updates Guidelines for the Management of Neonatal Hyperbilirubinemia https://pediatricsnationwide.org/wp-content/uploads/2022/09/AdobeStock_115709904_HRBW-1024x737.jpg 1024 737 Emily Siebenmorgen Emily Siebenmorgen https://secure.gravatar.com/avatar/80ad94df0a394e22ac60debb09a09c08?s=96&d=mm&r=g
Predicting Response to Bronchodilators in Infants with Bronchopulmonary DysplasiaPredicting Response to Bronchodilators in Infants with Bronchopulmonary Dysplasia https://pediatricsnationwide.org/wp-content/uploads/2022/07/091021BS0082-1024x683.jpg 1024 683 Mary Bates, PhD Mary Bates, PhD https://secure.gravatar.com/avatar/c6233ca2b7754ab7c4c820e14eb518c8?s=96&d=mm&r=g
Anal Sphincter Botox Injections for Children With Severe ConstipationAnal Sphincter Botox Injections for Children With Severe Constipation https://pediatricsnationwide.org/wp-content/uploads/2021/03/AdobeStock_124856540-1024x680.jpg 1024 680 Mary Bates, PhD Mary Bates, PhD https://secure.gravatar.com/avatar/c6233ca2b7754ab7c4c820e14eb518c8?s=96&d=mm&r=g